Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

66.7%

4 terminated/withdrawn out of 6 trials

Success Rate

20.0%

-66.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

400%

4 of 1 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

Phase 1

3(50.0%)

Phase 2

2(33.3%)

Phase 3

1(16.7%)

6Total

Phase 1(3)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT03829254Phase 1Recruiting

A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma

Role: lead

NCT05678257Phase 2Terminated

A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer

Role: lead

NCT05714553Phase 1Terminated

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Role: lead

NCT03428958Phase 1Completed

A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

Role: lead

NCT04163900Phase 3Terminated

Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer

Role: lead

NCT03146663Phase 2Terminated

NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer

Role: lead

All 6 trials loaded